Zivo Bioscience Financials
This page shows Zivo Bioscience (ZIVOW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Zivo Bioscience passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Zivo Bioscience generates $0.32 in operating cash flow (-$4.3M OCF vs -$13.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Zivo Bioscience generated $157K in revenue in fiscal year 2024. This represents an increase of 468.6% from the prior year.
Zivo Bioscience reported -$13.4M in net income in fiscal year 2024. This represents a decrease of 72.1% from the prior year.
Zivo Bioscience earned $-4.23 per diluted share (EPS) in fiscal year 2024. This represents an increase of 8.0% from the prior year.
Zivo Bioscience held $1.5M in cash against $0 in long-term debt as of fiscal year 2024.
Zivo Bioscience had 4M shares outstanding in fiscal year 2024. This represents an increase of 52.0% from the prior year.
Zivo Bioscience's gross margin was 31.1% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 10.8 percentage points from the prior year.
Zivo Bioscience's operating margin was -8498.9% in fiscal year 2024, reflecting core business profitability. This is up 17768.8 percentage points from the prior year.
Zivo Bioscience's net profit margin was -8513.4% in fiscal year 2024, showing the share of revenue converted to profit. This is up 19613.8 percentage points from the prior year.
Zivo Bioscience invested $3.1M in research and development in fiscal year 2024. This represents an increase of 127.7% from the prior year.
ZIVOW Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $66K+22.9% | $53K | $0 | N/A | $32K | $0-100.0% | $36K | N/A |
| Cost of Revenue | $44K+25.0% | $35K | $0 | N/A | $22K | $0-100.0% | $23K | N/A |
| Gross Profit | $21K+18.8% | $18K | $0 | N/A | $9K | $0-100.0% | $13K | N/A |
| R&D Expenses | $203K-57.6% | $480K-82.7% | $2.8M | N/A | $326K-85.5% | $2.3M+620.1% | $313K | N/A |
| SG&A Expenses | $836K-28.6% | $1.2M-18.6% | $1.4M | N/A | $1.9M-67.5% | $6.0M+512.7% | $976K | N/A |
| Operating Income | -$1.0M+37.6% | -$1.6M+61.2% | -$4.2M | N/A | -$2.3M+72.5% | -$8.2M-545.0% | -$1.3M | N/A |
| Interest Expense | $13K+76.1% | $7K+206.7% | $2K | N/A | $9K+26.5% | $7K+155.6% | $3K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | $0 | N/A |
| Net Income | -$1.0M+37.0% | -$1.6M+61.1% | -$4.2M | N/A | -$2.3M+72.5% | -$8.2M-544.2% | -$1.3M | N/A |
| EPS (Diluted) | $-0.27+37.2% | $-0.43+61.6% | $-1.12 | N/A | $-0.67+75.9% | $-2.78-491.5% | $-0.47 | N/A |
ZIVOW Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $559K-20.5% | $703K-47.2% | $1.3M-19.0% | $1.6M+231.6% | $496K-13.9% | $576K-29.5% | $816K+46.9% | $556K |
| Current Assets | $281K-31.3% | $410K-59.9% | $1.0M-37.5% | $1.6M+274.6% | $437K-11.8% | $495K-30.3% | $711K+67.1% | $425K |
| Cash & Equivalents | $57K+482.5% | $10K-98.1% | $517K-66.5% | $1.5M+867.6% | $159K+6364.0% | $2K-98.2% | $139K-49.5% | $274K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $0-100.0% | $34K | $0-100.0% | $2K-92.0% | $28K | $0-100.0% | $4K0.0% | $4K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.8M+18.6% | $3.2M+10.0% | $2.9M+36.6% | $2.2M-16.3% | $2.6M-10.2% | $2.9M-6.9% | $3.1M+11.7% | $2.8M |
| Current Liabilities | $3.6M+22.1% | $3.0M+13.3% | $2.6M+28.0% | $2.0M-20.8% | $2.6M-10.2% | $2.9M-6.9% | $3.1M+11.7% | $2.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$3.3M-29.4% | -$2.5M-57.1% | -$1.6M-214.1% | -$515K+75.3% | -$2.1M+9.3% | -$2.3M-1.2% | -$2.3M-2.9% | -$2.2M |
| Retained Earnings | -$143.9M-0.7% | -$142.8M-1.2% | -$141.2M-3.1% | -$137.0M-1.2% | -$135.4M-1.7% | -$133.1M-6.6% | -$124.9M-1.0% | -$123.6M |
ZIVOW Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$267K+44.0% | -$476K+66.7% | -$1.4M-57.9% | -$906K+16.5% | -$1.1M-74.0% | -$624K+63.3% | -$1.7M-137.4% | -$716K |
| Capital Expenditures | N/A | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | -$783K | N/A | N/A | N/A |
| Investing Cash Flow | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing Cash Flow | $314K+1114.2% | -$31K-107.6% | $405K-82.3% | $2.3M+84.3% | $1.2M+154.8% | $487K-68.8% | $1.6M+416.1% | -$495K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ZIVOW Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 32.4%-1.1pp | 33.6% | N/A | N/A | 30.0% | N/A | 35.0% | N/A |
| Operating Margin | -1551.8%+1506.0pp | -3057.8% | N/A | N/A | -7174.7% | N/A | -3571.8% | N/A |
| Net Margin | -1574.2%+1497.4pp | -3071.6% | N/A | N/A | -7201.9% | N/A | -3579.2% | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -184.7%+48.6pp | -233.2%+83.1pp | -316.3% | N/A | -457.8%+973.2pp | -1431.0%-1274.3pp | -156.6% | N/A |
| Current Ratio | 0.08-0.1 | 0.14-0.3 | 0.39-0.4 | 0.80+0.6 | 0.170.0 | 0.17-0.1 | 0.23+0.1 | 0.15 |
| Debt-to-Equity | -1.17+0.1 | -1.28+0.5 | -1.82+2.4 | -4.19-3.0 | -1.24+0.0 | -1.25+0.1 | -1.36-0.1 | -1.25 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$515K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.80), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Zivo Bioscience's annual revenue?
Zivo Bioscience (ZIVOW) reported $157K in total revenue for fiscal year 2024. This represents a 468.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Zivo Bioscience's revenue growing?
Zivo Bioscience (ZIVOW) revenue grew by 468.6% year-over-year, from $28K to $157K in fiscal year 2024.
Is Zivo Bioscience profitable?
No, Zivo Bioscience (ZIVOW) reported a net income of -$13.4M in fiscal year 2024, with a net profit margin of -8513.4%.
What is Zivo Bioscience's earnings per share (EPS)?
Zivo Bioscience (ZIVOW) reported diluted earnings per share of $-4.23 for fiscal year 2024. This represents a 8.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Zivo Bioscience's gross margin?
Zivo Bioscience (ZIVOW) had a gross margin of 31.1% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Zivo Bioscience's operating margin?
Zivo Bioscience (ZIVOW) had an operating margin of -8498.9% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Zivo Bioscience's net profit margin?
Zivo Bioscience (ZIVOW) had a net profit margin of -8513.4% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Zivo Bioscience's operating cash flow?
Zivo Bioscience (ZIVOW) generated -$4.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Zivo Bioscience's total assets?
Zivo Bioscience (ZIVOW) had $1.6M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Zivo Bioscience spend on research and development?
Zivo Bioscience (ZIVOW) invested $3.1M in research and development during fiscal year 2024.
How many shares does Zivo Bioscience have outstanding?
Zivo Bioscience (ZIVOW) had 4M shares outstanding as of fiscal year 2024.
What is Zivo Bioscience's current ratio?
Zivo Bioscience (ZIVOW) had a current ratio of 0.80 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Zivo Bioscience's debt-to-equity ratio?
Zivo Bioscience (ZIVOW) had a debt-to-equity ratio of -4.19 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Zivo Bioscience's return on assets (ROA)?
Zivo Bioscience (ZIVOW) had a return on assets of -814.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Zivo Bioscience's cash runway?
Based on fiscal year 2024 data, Zivo Bioscience (ZIVOW) had $1.5M in cash against an annual operating cash burn of $4.3M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Zivo Bioscience's debt-to-equity ratio negative or unusual?
Zivo Bioscience (ZIVOW) has negative shareholder equity of -$515K as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Zivo Bioscience's Piotroski F-Score?
Zivo Bioscience (ZIVOW) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Zivo Bioscience's earnings high quality?
Zivo Bioscience (ZIVOW) has an earnings quality ratio of 0.32x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.